Wacker Chemie AG. (12/17/24). "Press Release: Wacker Biosolutions under New Leadership". Munich.

	Organisation	Wacker Biosolutions division
	Today	Chemovator GmbH
	Group	Wacker (Group)
	Organisation 2	University of Bremen
	Product	contract manufacturing (biologicals)
	Product 2	plasmid DNA (pDNA)
	Person	Wiedemann, Mathias (Wacker 202501– President of Wacker Biosolutions joined Wacker in 2011)
	Person 2	Leonhartsberger, Susanne (Wacker 202007–202412 Head of Biosolutions joined Wacker in 2001 LEFT 12/24)

Mathias Wiedemann will take over as president of WACKER BIOSOLUTIONS on January 1, 2025. He succeeds Susanne Leonhartsberger, who will leave the company at her own request at the end of 2024.

“I am delighted that we have been able to recruit Mathias Wiedemann, an outstanding colleague from our own midst, to head our biotech division. I wish him every success in his new role,” says WACKER CEO Christian Hartel. Wiedemann previously headed WACKER’s POLYMERS business in the USA. His new assignment sees him returning to Munich. “BIOSOLUTIONS offers exciting products and services. I look forward to meeting this challenge. We are pursuing ambitious growth targets with a great team. Our goal is to generate one billion euros in sales in 2030,” explains Wiedemann.

Mathias Wiedemann studied engineering and business administration at the University of Bremen, where he earned his doctorate in engineering on a scholarship from WACKER BIOSOLUTIONS. He joined WACKER as a project engineer in 2011. After holding several specialist and managerial positions in Germany and abroad, he was most recently responsible for POLYMERS’ business in North and Central America. In May 2024, Wiedemann was also appointed CFO of Wacker Chemical Corporation.

Susanne Leonhartsberger took charge of the BIOSOLUTIONS division in 2020. She joined WACKER in 2001 and has been instrumental in developing BIOSOLUTIONS in various functions both in Germany and elsewhere. Development milestones under her leadership include the establishment of an mRNA competence center in Halle/Saale, Germany, in the context of the pandemic-preparedness agreements with the German government. “Susanne Leonhartsberger has taken BIOSOLUTIONS a decisive step forward on its growth path,” emphasizes Hartel. “On behalf of the entire Executive Board, I would like to thank her for her commitment and dedication. We wish her all the best for the future.”

About WACKER BIOSOLUTIONS

Using biotech processes, WACKER BIOSOLUTIONS provides tailored, innovative solutions and products to the life-science sector – including pharmaceutical proteins, messenger RNA, plasmid DNA, live therapeutic products (LBPs) and bacterial-based vaccines as well as cyclodextrins and fermentative L-cysteine. The portfolio is additionally complemented with catalog chemicals such as acetylacetone. The division focuses on growth sectors, such as food ingredients, pharmaceutical actives and agrochemicals. WACKER BIOSOLUTIONS is the WACKER Group’s life-sciences division.

For further information, please contact:

Wacker Chemie AG
Media Relations & Information
Dr. Karsten Werth
Tel. +49 89 6279-1573
[email protected]
www.wacker.com

Follow us on:

The Company in Brief:

WACKER is a global company with state-of-the-art specialty chemical products found in countless everyday items, ranging from tile adhesives to computer chips. The company has a global network of 27 production sites, 22 technical
competence centers and 48 sales offices. With around 16,400 employees, WACKER generated annual sales of around €6.4 billion in fiscal 2023. WACKER operates through four business divisions. The chemical divisions WACKER SILICONES and WACKER POLYMERS supply products (silicones, polymeric binders) for the automotive, construction, chemical, consumer goods and medical technology industries. WACKER BIOSOLUTIONS, the life sciences division, specializes in bioengineered products such as biopharmaceuticals and food additives. WACKER POLYSILICON produces hyperpure polysilicon for the semiconductor and photovoltaic industries.

Record changed: 2025-01-20